Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) with greater receptor selectivity and diminished risk of hyperkalemia compared with the steroidal MRAs (e.g., spironolactone and eplerenone). The gene discussed is NR3C2; the disease is Hyperkalemia.